Sani H. Kizilbash

Mayo Clinic (Rochester)
Rochester, Minnesota, United States

Sani H Kizilbash, MBBS MPH is an Associate Professor of Oncology at Mayo Clinic (Rochester, MN) with interests in central nervous system malignancies and early phase clinical trial development. Dr. Kizilbash has served as the site principal investigator for at least 15 clinical trials (investigator initiated, cooperative group and industry-initiated). Significant leadership roles in clinical trial development include: (a) Lead PI, NCI ETCTN Phase 1b trial 10218 (NCT03528642): Telaglenastat in combination with radiation and temozolomide in IDH-mutant astrocytoma, (b) Lead PI, Mayo Clinic Phase 1 trial MC1914 (NCT04197934): WSD0922 in EGFR mutant high-grade astrocytoma and non-small cell lung with CNS metastases [R01 funded], (c) 3) Co-Chair, Alliance phase 2/3 trial A071101 (NCT02152982): Temozolomide with veliparib/placebo in MGMT promoter hypermethylated glioblastoma. Active federal funding includes grants from the National Cancer Institute, National Institute of Neurological Disorders and Stroke and the Food and Drug Administration. Leadership roles within Mayo Clinic include: (a) Chair for the Medical Oncology Brain Tumor Practice at Mayo Clinic (Rochester, MN), and (b) Co-Chair for the Protocol Review and Monitoring Committee for the Mayo Clinic Cancer Center. Finally, he currently mentors four junior faculty on clinical trial development for central nervous system malignancies, along with several fellows, residents, and allied health staff on various clinical and translational research projects.